82 related articles for article (PubMed ID: 17327617)
1. Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
Personeni N
J Clin Oncol; 2007 Mar; 25(7):910; author reply 911. PubMed ID: 17327617
[No Abstract] [Full Text] [Related]
2. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Cappuzzo F
J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643
[No Abstract] [Full Text] [Related]
5. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Garland LL; Rankin C; Gandara DR; Rivkin SE; Scott KM; Nagle RB; Klein-Szanto AJ; Testa JR; Altomare DA; Borden EC
J Clin Oncol; 2007 Jun; 25(17):2406-13. PubMed ID: 17557954
[TBL] [Abstract][Full Text] [Related]
7. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
Langer CJ
J Clin Oncol; 2007 Mar; 25(7):751-3. PubMed ID: 17228017
[No Abstract] [Full Text] [Related]
8. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Cappuzzo F; Ligorio C; Jänne PA; Toschi L; Rossi E; Trisolini R; Paioli D; Holmes AJ; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Ciardiello F; Patelli M; Crino L; Varella-Garcia M
J Clin Oncol; 2007 Jun; 25(16):2248-55. PubMed ID: 17538169
[TBL] [Abstract][Full Text] [Related]
9. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
De Silva N; Schulz L; Paterson A; Qain W; Secrier M; Godfrey E; Cheow H; O'Donovan M; Lao-Sirieix P; Jobanputra M; Hochhauser D; Fitzgerald R; Ford H
Br J Cancer; 2015 Nov; 113(9):1305-12. PubMed ID: 26484410
[TBL] [Abstract][Full Text] [Related]
10. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib and gastrointestinal ulcer.
Kim YH; Masago K; Mishima M
J Thorac Oncol; 2010 Jul; 5(7):1108-9. PubMed ID: 20581582
[No Abstract] [Full Text] [Related]
12. Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma.
Leone F; Pignochino Y; Cavalloni G; Aglietta M
J Clin Oncol; 2007 Mar; 25(9):1145; author reply 1145-6. PubMed ID: 17369582
[No Abstract] [Full Text] [Related]
13. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Wong AS; Seto KY; Chin TM; Soo RA
J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
[No Abstract] [Full Text] [Related]
14. Treatment of multiple keratoacanthomas with erlotinib.
Reid DC; Guitart J; Agulnik M; Lacouture ME
Int J Clin Oncol; 2010 Aug; 15(4):413-5. PubMed ID: 20221661
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Yamasaki F; Johansen MJ; Zhang D; Krishnamurthy S; Felix E; Bartholomeusz C; Aguilar RJ; Kurisu K; Mills GB; Hortobagyi GN; Ueno NT
Cancer Res; 2007 Jun; 67(12):5779-88. PubMed ID: 17575145
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib in lung cancer.
Pao W; Ladanyi M; Miller VA;
N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240471
[No Abstract] [Full Text] [Related]
17. Response of glioblastomas to EGFR kinase inhibitors.
Lassman AB; Abrey LE; Gilbert MR
N Engl J Med; 2006 Feb; 354(5):525-6; author reply 525-6. PubMed ID: 16452568
[No Abstract] [Full Text] [Related]
18. Treatment of lung cancer.
Wang J; Qiu JH
N Engl J Med; 2009 Dec; 361(25):2486; author reply 2487. PubMed ID: 20050214
[No Abstract] [Full Text] [Related]
19. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.
Miyanaga A; Gemma A; Ando M; Kosaihira S; Noro R; Minegishi Y; Kataoka K; Nara M; Okano T; Miyazawa H; Tanaka T; Yoshimura A; Kobayashi K; Iwanami H; Hagiwara K; Tsuboi E; Kudoh S
Oncol Rep; 2008 Feb; 19(2):377-83. PubMed ID: 18202784
[TBL] [Abstract][Full Text] [Related]
20. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
